Primary Ciliary Dyskinesia (PCD) Clinical Trial Pipeline Analysis: Emerging mRNA Therapies Advancing the Future of PCD Treatment | DelveInsight

DelveInsight's Primary Ciliary Dyskinesia (PCD) Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Primary Ciliary Dyskinesia (PCD) therapies in various stages of clinical development, highlighting major pharmaceutical companies working to advance the pipeline landscape and future growth opportunities in the Primary Ciliary Dyskinesia therapeutic market.

Key takeaways from the Primary Ciliary Dyskinesia (PCD) Clinical Trial Landscape Report
• DelveInsight's Primary Ciliary Dyskinesia (PCD) pipeline report depicts an evolving therapeutic landscape with active players developing innovative pipeline therapies for PCD treatment.
• Key Primary Ciliary Dyskinesia (PCD) companies such as ReCode Therapeutics, Ethris, and others
• Promising Primary Ciliary Dyskinesia (PCD) pipeline therapies in various stages of development include RCT1100, ETH42, and others

Request a sample and discover the recent advances in Primary Ciliary Dyskinesia (PCD) treatment drugs https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-pcd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Primary Ciliary Dyskinesia (PCD)?
Primary Ciliary Dyskinesia (PCD) is a rare genetic disorder that affects the structure and function of motile cilia, primarily within the respiratory epithelium. Dysfunctional ciliary movement impairs mucociliary clearance, resulting in chronic respiratory infections, inflammation, and progressive lung complications.
PCD is predominantly inherited in an autosomal recessive pattern, although autosomal dominant and X-linked inheritance have also been reported. More than 55 disease-causing genes have been identified, with mutations affecting proteins critical for ciliary structure and movement. Certain causative genes may also lead to laterality defects such as situs inversus and heterotaxy during embryonic development.
Symptoms of PCD commonly include chronic wet cough, persistent nasal congestion, recurrent ear infections, pneumonia, and progressive respiratory disease beginning in infancy. Diagnosis involves clinical evaluation, family history, genetic testing, electron microscopy, video microscopy, nasal nitric oxide measurement, and pulmonary function testing. Current treatment strategies focus on symptom management through airway clearance, chest physiotherapy, antimicrobial therapy, vaccinations, and supportive respiratory care.

Emerging Primary Ciliary Dyskinesia (PCD) Drug Profiles

RCT1100: ReCode Therapeutics
RCT1100 is an investigational inhaled mRNA-based therapy being developed by ReCode Therapeutics for Primary Ciliary Dyskinesia caused by pathogenic mutations in the DNAI1 gene. The therapy is designed to restore ciliary function by delivering DNAI1-mRNA directly to the lungs through inhalation. By targeting the underlying genetic defect responsible for impaired ciliary movement, RCT1100 aims to address the root cause of the disease rather than only managing symptoms. The therapy is currently in Phase I/II clinical development.
ETH42: Ethris
ETH42 is an investigational therapy being developed by Ethris for the treatment of Primary Ciliary Dyskinesia. The therapy focuses on protein synthesis stimulation approaches aimed at restoring ciliary function and improving respiratory outcomes in PCD patients. ETH42 is currently in preclinical development.

Learn more about the novel and emerging Primary Ciliary Dyskinesia (PCD) pipeline therapies https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-pcd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the Primary Ciliary Dyskinesia (PCD) Clinical Trial Landscape
• In October 2024, ReCode Therapeutics initiated a Phase Ib open-label clinical study evaluating inhaled RCT1100 in adults with Primary Ciliary Dyskinesia caused by pathogenic mutations in the DNAI1 gene.
• In June 2024, ReCode Therapeutics announced that the US Food and Drug Administration (FDA) granted Orphan Drug Designation to RCT1100 for the treatment of Primary Ciliary Dyskinesia (PCD).
• In January 2024, ReCode Therapeutics announced that a patient had been treated with RCT1100, an investigational mRNA-based therapy being evaluated in a Phase I study for PCD patients with DNAI1 mutations.
• In May 2022, ReCode Therapeutics presented preclinical data at the American Thoracic Society (ATS) International Conference demonstrating successful restoration of ciliary function using inhaled SORT LNP-formulated DNAI1 mRNA in PCD models.
• In October 2024, PCD Research and NATA jointly awarded a £250,000 research grant to support development of mRNA therapies targeting faulty CCDC39 protein expression in PCD.

Scope of the Primary Ciliary Dyskinesia (PCD) Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase I/II, Phase II
• Therapeutics Assessment By Route of Administration: Inhalation, Oral, Subcutaneous
• Therapeutics Assessment By Molecule Type: mRNA therapy
• Key Primary Ciliary Dyskinesia (PCD) Companies: ReCode Therapeutics, Ethris, and others
• Key Primary Ciliary Dyskinesia (PCD) Pipeline Therapies: RCT1100, ETH42, and others

Dive deep into rich insights for new drugs for Primary Ciliary Dyskinesia (PCD) treatment, visit https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-pcd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. Primary Ciliary Dyskinesia (PCD) Pipeline Report Introduction
2. Primary Ciliary Dyskinesia (PCD) Pipeline Report Executive Summary
3. Primary Ciliary Dyskinesia (PCD) Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Primary Ciliary Dyskinesia (PCD) Pipeline Therapeutics
6. Primary Ciliary Dyskinesia (PCD) Pipeline: Late Stage Products (Phase III)
7. Primary Ciliary Dyskinesia (PCD) Pipeline: Mid Stage Products (Phase II)
8. Primary Ciliary Dyskinesia (PCD) Pipeline: Early Stage Products (Phase I/II)
9. Primary Ciliary Dyskinesia (PCD) Pipeline Therapeutics Assessment
10. Inactive Products in the Primary Ciliary Dyskinesia (PCD) Pipeline
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products in the Primary Ciliary Dyskinesia (PCD) Pipeline
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

For further information on the Primary Ciliary Dyskinesia (PCD) pipeline therapeutics, reach out https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-pcd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.